Cargando…
Metformin reverses stem cell-like HepG2 sphere formation and resistance to sorafenib by attenuating epithelial-mesenchymal transformation
Cancer stem cells (CSCs) have been reported to be associated with the recurrence and drug resistance of liver cancer. In the present study, stem cell-like HepG2 cell spheres were enriched using stem cell conditioned culture medium. As expected, stem-like HepG2 cell spheres exhibited increased resist...
Autores principales: | Feng, Yan, Guo, Xing, Huang, Xinping, Wu, Manya, Li, Xin, Wu, Shushu, Luo, Xiaoling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131649/ https://www.ncbi.nlm.nih.gov/pubmed/30106125 http://dx.doi.org/10.3892/mmr.2018.9348 |
Ejemplares similares
-
PDCD2 sensitizes HepG2 cells to sorafenib by suppressing epithelial-mesenchymal transition
por: Liu, Hongyu, et al.
Publicado: (2019) -
Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells
por: Taha, Amna Mohamed, et al.
Publicado: (2022) -
The Effect of Alpha Mangostin on Epithelial-Mesenchymal Transition on Human Hepatocellular Carcinoma HepG2 Cells Surviving Sorafenib via TGF-β/Smad Pathways
por: Adenina, Syarinta, et al.
Publicado: (2020) -
ESC reverses epithelial mesenchymal transition induced by transforming growth factor-β via inhibition of Smad signal pathway in HepG2 liver cancer cells
por: Liu, Xiao-Ni, et al.
Publicado: (2015) -
AngII induces HepG2 cells to activate epithelial-mesenchymal transition
por: Qi, Minghua, et al.
Publicado: (2018)